ArticleInvestigational new drugs2014

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

Masafumi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.